Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis
Authors' conclusion
In this descriptive study, intranasal ketamine served as an acute treatment for refractory chronic migraine by reducing headache intensity and improving quality of life with relatively tolerable adverse events. Most patients found intranasal ketamine effective and continued to use it despite these adverse events.
Study context
- Population
- Patients with refractory chronic migraine at a single tertiary headache center242 screened
- Participants
- 169 patients
- Outcome
- Clinical effectiveness and tolerability of intranasal ketamine
Methodological detailssingle-centre, descriptive, chart review and structured telephone interviews
- Single-centre
- Descriptive
- Chart review and structured telephone interviews
Main finding
As reported in the abstract
Patient-reported effectiveness and quality of life · At interview
Intranasal ketamine reported as 'very effective'
49.1%
Quality of life 'much better'
35.5%
Remained current users at interview
65.1%
Observational data: associations, not effects.
Further findings
Use pattern
- Sprays per day, median (IQR)
- 6 (6)
- Spray-use days per month, median (IQR)
- 10 (11)
Safety
At least one adverse event · At interview
- Reported at least one adverse event
- 74.0%
Original publication
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis. Reg Anesth Pain Med. Published 30 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →